Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 79.40
Bid: 75.00
Ask: 79.00
Change: 7.40 (10.28%)
Spread: 4.00 (5.333%)
Open: 73.00
High: 79.40
Low: 73.00
Prev. Close: 72.00
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

David Allmond to be CEO, Graham Mullis to retire

29 Jul 2021 07:00

RNS Number : 8330G
Novacyt S.A.
29 July 2021
 

 

 

Novacyt S.A.

 

("Novacyt", the "Company" or the "Group")

 

David Allmond announced as CEO following decision by Graham Mullis to retire

 

Paris, France and Camberley, UK - 29 July 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a leading international specialist in clinical diagnostics, announces the appointment of David Allmond as CEO and a member of the Board of Directors effective from 18 October 2021. At that time Graham Mullis, having informed the Board that he wishes to retire after 13 years with the expanded Group, will stand down as CEO and board member.

 

David, aged 51, brings relevant leadership experience in life science companies experiencing significant development and growth, and developing businesses into new global markets. Currently he is Chief Business Officer at Amryt Pharma (Nasdaq: AMYT, AIM: AMYT), where he has played a key role in developing the company into a leading global rare and orphan disease drug company. Earlier in his career David held sales and marketing roles of increasing seniority at Amgen, Celgene, and Aegerion Pharmaceuticals. David received a BSc in microbiology from Imperial College. David will be supported by Novacyt's recently strengthened executive management team.

 

Graham will be retiring after 13 years with the wider business, both as CEO of Novacyt and formerly CEO of Lab21, which was acquired by the Group in 2014. Graham is committed to ensuring a smooth transition with David and will continue to lead the Group as CEO until David joins the Company.

 

James Wakefield, Chairman of Novacyt, added:

"The Board is highly confident that, after an extensive search, we have found the right leader for Novacyt's next chapter of growth, following Graham's decision to retire. We look forward to working with David and the recently strengthened senior management team to deliver on the Company's strategy of organic, R&D and acquisitive growth that we recently reiterated at our full year results.

 

"The Group owes Graham a huge debt of gratitude for his hard work, determination and leadership. He leaves a legacy of having created one of the UK's leading diagnostic businesses and should be proud of the role the Company has played, and continues to play, in supporting nations and businesses in their response to the COVID-19 pandemic."

 

David Allmond, CEO-elect of Novacyt, commented: 

"I am excited to be joining Novacyt at a pivotal phase in its development and I am looking forward to building upon Graham's outstanding work with the business over the past 13 years. Novacyt is poised for its next phase of growth and I am confident I can lead the Company effectively through this period, working closely with the excellent management team and Board to make a significant contribution to global health and deliver sustained and ongoing value to our shareholders."

 

Graham Mullis, CEO of Novacyt, commented: 

"It has been, and remains, a privilege to have led and worked with the exceptional team at Novacyt. The Company is far more than the success it has enjoyed during the last 18 months as we have played an important part in responding to the COVID-19 pandemic. I believe the Company has the right foundations and culture in place to deliver on its strategy that will enable it to cement its position as a leading specialist diagnostics business. It is therefore with great pride that I hand over leadership of the Company to David, confident in his abilities to take the Company forward to even greater successes.

 

"Finally, I would like to thank the Board and all my colleagues for their advice and support over the years. I look forward to watching Novacyt continue on its exciting journey."

 

David's position on the board of Novacyt will be proposed for ratification by shareholders at the Company's 2022 Annual General Meeting.

 

The information required by Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies in relation to the appointment of David James Allmond (age 51) is as follows:

 

Current directorships

Past directorships held within last five years

Aegerion Pharma Ltd

Amryt Pharma Italy SRL

Myeloma UK

Peppered Moth Marketing Limited

Vitixity Limited

 

There are no other disclosures required in accordance with Schedule 2(g) of the AIM Rules.

 

- End -

 

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / alex.shaw@fticonsulting.com 

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 47

arnaud.decheffontaines@fticonsulting.com 

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCRPMMTMTJTTRB
Date   Source Headline
1st Jun 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20237:00 amRNSPublication of Annual Report and AGM voting
10th May 20237:00 amRNSNotice of AGM
2nd May 202312:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSFinal Results
17th Apr 20237:00 amRNSNotice of Results
3rd Apr 20231:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Mar 20234:15 pmRNSLiquidity Agreement and Total Voting Rights
1st Feb 20231:30 pmRNSLiquidity Agreement and Total Voting Rights
30th Jan 20237:00 amRNSDHSC Claim update – Trial date listed
26th Jan 20237:00 amRNSFull Year 2022 Trading Update
6th Jan 202312:15 pmRNSHoldings in Company
3rd Jan 202312:30 pmRNSLiquidity Agreement and Total Voting Rights
7th Dec 20227:00 amRNSNon-Executive Director Change
6th Dec 20227:00 amRNSApproval of genesig COVID-19 3G PCR test in UK
1st Dec 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20225:00 pmRNSLiquidity Agreement and Total Voting Rights
27th Oct 20226:45 pmRNSCORRECTION: UK CTDA approval of Winterplex 3G
26th Oct 20227:00 amRNSUK Approval of genesig® SARS-CoV-2 Winterplex® 3G
3rd Oct 20223:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Sep 20227:00 amRNSHalf year 2022 results
15th Sep 20227:00 amRNSNotice of Results and Investor Presentation
1st Sep 202212:00 pmRNSLiquidity Agreement and Total Voting Rights
4th Aug 20227:00 amRNSLaunch of first fully lyophilised PROmate® assays
1st Aug 20222:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Jul 20227:00 amRNSLaunch of research-use-only adenovirus F41 assay
20th Jul 20223:00 pmRNSResults of AGM
15th Jul 20227:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSApproval of exsig™ COVID-19 Direct test in the UK
7th Jul 20223:00 pmRNSDirector/PDMR Shareholding
7th Jul 20227:00 amRNSTrading update and progress against strategy
5th Jul 202211:45 amRNSHoldings in Company
1st Jul 202212:30 pmRNSLiquidity Agreement and Total Voting Rights
28th Jun 20227:00 amRNSLaunch of monkeypox assay
21st Jun 20222:00 pmRNSNotice of rescheduled AGM
16th Jun 20227:00 amRNSDHSC dispute update
13th Jun 20227:00 amRNSAGM Voting
1st Jun 20221:00 pmRNSLiquidity Agreement and Total Voting Rights
1st Jun 20227:00 amRNSCTDA approval and CE mark
1st Jun 20227:00 amRNSPublication of Annual Report and AGM voting
13th May 20227:00 amRNSNotice of Annual General Meeting
3rd May 202212:21 pmRNSLiquidity Agreement Update and Total Voting Rights
28th Apr 20227:00 amRNSFull year results and update on growth strategy
26th Apr 20227:00 amRNSDHSC dispute update
20th Apr 20227:00 amRNSNotice of Results and Investor Presentation
12th Apr 20227:00 amRNSApproval of COVID-19 test under CTDA legislation
1st Apr 202211:45 amRNSLiquidity Agreement Update and Total Voting Rights
25th Mar 20225:25 pmRNSDirector/PDMR Shareholding
18th Mar 20226:00 pmRNSDirector/PCA Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.